{"id":239795,"date":"2021-06-01T15:02:15","date_gmt":"2021-06-01T19:02:15","guid":{"rendered":"https:\/\/oncubanews.com\/en\/?p=239795"},"modified":"2021-06-01T15:02:15","modified_gmt":"2021-06-01T19:02:15","slug":"convalescents-vaccinated-with-soberana-plus-have-highest-amount-of-antibodies-against-the-coronavirus-in-cuba","status":"publish","type":"post","link":"https:\/\/oncubanews.com\/en\/coronavirus\/convalescents-vaccinated-with-soberana-plus-have-highest-amount-of-antibodies-against-the-coronavirus-in-cuba\/","title":{"rendered":"Convalescents vaccinated with Soberana Plus have highest amount of antibodies against the coronavirus in Cuba"},"content":{"rendered":"

About to conclude the inoculation of the volunteers of phase II clinical trial with the Cuban <\/span>Soberana Plus<\/span><\/a> vaccine candidate, its developers affirm that the convalescents from <\/span>COVID-19<\/span><\/a> who received this drug are those with the most antibodies against the coronavirus in Cuba.<\/span><\/p>\n

The principal investigator of the clinical trials, Arturo Chang, pointed out that as part of the studies, the levels of antibodies have been evaluated, which turned out to be higher than those of convalescent patients without vaccination compared to those who received two doses of Soberana 02 plus the booster dose of Soberana Plus, reported the <\/span>Agencia Cubana de Noticias (ACN)<\/span><\/a> news agency.<\/span><\/p>\n

Cited by the agency, Chang clarified that these results were obtained in a previous Phase I trial based on the comparison of the antibodies developed by those inoculated with the injectable, created by the Finlay Vaccine Institute, in relation to those produced naturally when infected with SARS-CoV-2.<\/span><\/p>\n

\u201cThose people who recovered from the disease and were left with high antibody titers became part of the robust panel of Cuban convalescents, difficult to overcome, but after a dose of Soberana Plus in those who suffered from the virus \u2014 and were left with low antibody titers \u2014 it was possible to match and even exceed the panel,\u201d explained the expert, who, however, did not offer figures to detail the comparison.<\/span><\/p>\n

Likewise, the specialist stressed that the vaccine candidate has the potential to increase the immunity of convalescents with the application of a single dose, and assured that so far few adverse events have been registered \u201cso it does not offer any risk to elderly people.\u201d<\/span><\/p>\n

En la recta final ensayo cl\u00ednico fase II del candidato vacunal cubano Soberana Plus<\/a><\/p><\/blockquote>\n